

독일 의료용 대마초 시장에 서비스를 제공하는 수익성 높은 고성장 원격



MERGERSCORP

빠르게 확장 가능한 완전 원격 원격 의료 및 디지털 처방, EU 국경 간 프레임워크에 따라 운영되는 GDPR 준수 플랫폼을 확보할 수 있는 특별한 기회입니다. 이 비즈니스는 독일에서 20,000명 이상의 환자와 면허를 소지한 의사 및 약국을 연결합니다.

보유 라이선스

EU 국경 간 원격 의료 프레임워크에 따라 운영됩니다(독일 및 폴란드에서 면허를 취득한 의사). GDPR을 준수하는 플랫폼. 직접 대마초 취급 라이선스가 필요하지 않습니다.

리스팅 세부 정보

- 키프로스에 본사를 둔 이 회사는 원격 상담과 디지털 처방을 지원하는 완전한 디지털 원격 의료 플랫폼을 운영합니다.
- 2024년에 출시된 이 플랫폼은 약 20,000명의 환자에게 서비스를 제공하고 매월 6,500건 이상의 처방전을 처리했습니다.
- Facebook 광고 및 제휴 마케팅을 포함한 타겟 마케팅 캠페인을 시작하기 전에 확장성을 보장하기 위해 심층적인 프로세스 최적화에 집중하고, 사용자 경험을 향상시키기 위한 새로운 기능을 지속적으로 구현합니다.
- 마진이 60%를 초과하는 수익성 있는 비즈니스, 현재 월 14만 유로의 매출 실행률, 연간 20% 성장을 반영하여 연말까지 예상되는 150만 유로의 매출
- 환자 예약, 약국용 마케팅 서비스, 주요 생산업체와의 파트너십, 화이트 라벨 제품 제공을 통해 수익을 창출합니다.
- 프론트엔드 및 백엔드 프리랜서 전문가를 활용하여 최대 12명의 직원/프리랜서를 효율적으로 운영합니다.
- 자동화된 워크플로로 의사 상담 시간을 90%까지 단축하고, 플랫폼은 신속한 B2B 확장을 위한 화이트 라벨 기능을 지원합니다.

TARGET PRICE

\$ 0

GROSS REVENUE

\$ 1,680,000

EBITDA

\$ 1,008,000

BUSINESS TYPE

의료 서비스 비즈니스

COUNTRY

키프로스

BUSINESS ID

L#20261003

- 환자 수요 증가와 최근 독일 대마초 시장의 자유화로 인해 연간 15~20%의 성장이 예상됩니다.
- 계속기업 사업, 지적 재산, 브랜드, 환자 데이터베이스 및 소프트웨어 코드베이스가 포함된 완전 매각을 모색 중입니다.

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

MERGERSCORP

© 2026 MergersCorp M&A International. All rights reserved.

© 2026 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.

MERGERSCORP

WWW.MERGERSCORP.COM